SecBot SecBot
8-K ·Filed Nov 13, 2026

VIR

Vir Biotechnology, Inc.
BEARISH
Impact 5/10
Horizonimmediate Processed3d 2h ago SEC0001193125-26-461412
8-K material event: Items 1.01
Actionable Insight ▼ Bearish

Monitor the company's upcoming quarterly results for cash burn rate and progress on CHD program pre-commercial activities; the activist stake reduction one week prior suggests insider selling ahead of this dilutive raise.

DirectionBearish
Confidencehigh
Horizonimmediate
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vir Biotechnology priced an underwritten public offering of 15,000,000 shares of common stock at $10.00 per share, with gross proceeds of $150 million and expected net proceeds of approximately $140.4 million ($161.5 million if the underwriters' 30-day option for an additional 2,250,000 shares is fully exercised). The offering follows a recent activist stake reduction and a preliminary prospectus supplement filed one day earlier, and proceeds will fund pre-commercial activities for the CHD program, TCE oncology platform investments, and general corporate purposes. The 8.8% dilution (based on 171.3M shares outstanding) is a material negative event for existing shareholders.

Key Financial Metrics

Deal Value
$150.0M

Key Facts

  • 15,000,000 shares offered at $10.00 per share, gross proceeds $150 million
  • Underwriters have 30-day option for up to 2,250,000 additional shares
  • Expected net proceeds of approximately $140.4 million ($161.5 million if option fully exercised)
  • Underwriting discount of $0.60 per share; underwriters pay $9.40 per share
  • Offering priced on November 12, 2026, expected to close November 16, 2026
  • Proceeds to fund pre-commercial activities for CHD program, TCE oncology platform, and general corporate purposes
  • Follows activist stake reduction (SC 13D/A filed Nov 6, 2026) and preliminary prospectus supplement (424B5 filed Nov 12, 2026)

Financial Impact

Dilution of approximately 8.8% based on 171.3M shares outstanding; gross proceeds of $150 million; net proceeds of approximately $140.4 million

dilutioncash

Risk Factors

  • 8.8% dilution to existing shareholders from the base offering
  • Up to 10.1% dilution if the underwriters' option is fully exercised
  • Activist investor ARCH Venture Fund IX reduced its stake by 0.5% just 7 days before this offering, potentially signaling lack of confidence
  • Clinical-stage biotech with no approved products, raising cash through equity rather than revenue

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-461412
Document: d156106d8k.htm0001193125-26-461412
Document: d156106dex991.htm0001193125-26-461412
Document: d156106dex992.htm0001193125-26-461412
Document: d156106dex51.htm0001193125-26-461412
Document: 0001193125-26-461412-index-headers.html0001193125-26-461412
Document: 0001193125-26-461412-index.html0001193125-26-461412
Document: 0001193125-26-461412.txt0001193125-26-461412

Track record

36 reports on VIR

Performance horizon

4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +29.79% at T+5 after the Nov 6, 2026 report. 5 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today 424B5 Bearish 5/10 Entry $9.84 Now $9.58 +2.64% settles Nov 23
  2. Nov 13, 20263d ago 8-K Bearish 5/10 Viewing Entry $9.92 Now $9.58 +3.43% settles Nov 23
  3. Nov 12, 20264d ago 424B5 Bearish 5/10 Entry $9.96 Now $9.58 +3.82% settles Nov 20
  4. Nov 12, 20264d ago S-3ASR Neutral 3/10 Entry $9.96 Now $9.58 −3.82% settles Nov 20
  5. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $13.15 Now $9.58 −27.15% settles Nov 17
  6. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $13.65 to $9.58 Now $9.58 −29.79% ▼ −29.79% −28.10% vs SPY
  7. Nov 6, 202610d ago SC 13D/A Bearish 5/10 Entry $13.65 to $9.58 Now $9.58 +29.79% ▲ +29.79% +28.10% vs SPY
  8. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $11.02 to $12.12 Now $9.58 −13.07% ▲ +9.98% +6.69% vs SPY
  9. Nov 3, 202613d ago 144 Neutral 2/10 Entry $11.22 to $13.15 Now $9.58 −14.62% ▲ +17.20% +17.79% vs SPY
  10. Nov 2, 202614d ago 144 Neutral 1/10 Entry $11.00 to $13.65 Now $9.58 −12.91% ▲ +24.05% +23.97% vs SPY
Showing 10 of 36

US Market Status

Market Closed · Opens in 9h 12m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026